Sweeney et al. present results of CHAARTED trial at ASCO

So the data from the CHAARTED trial will be presented this afternoon at the ASCO meeting. This is the one really major and positive study result related to prostate cancer that we knew was coming at this meeting. … READ MORE …

Early chemotherapy after failure of first-line treatment — data from a Phase II trial

It remains unclear at this time whether the early use of chemotherapy in carefully selected men with intermediate- and high-risk forms of prostate cancer (while the cancer is still believed to be limited in its spread) is associated with superior clinical outcomes compared to other forms of therapy. … READ MORE …

Chemohormonal therapy + EBRT for treatment of locally advanced prostate cancer

Several years ago, Bolla et al. planned and carried out the major European trial showing that external beam radiation therapy with 3 years of androgen deprivation therapy (ADT, using goserelin acetate)  extended the prostate cancer-specific and the overall survival of patients with high-risk localized prostate cancer as compared to radiation alone. … READ MORE …